Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

Based on this new patent grant, management believes that it will be able to maintain the original royalty rate for J&J's Darzalex SC, in the EU through March 2029. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to$2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to$2.73. Year to date, shares of ALXO have plunged 40.9%. Halozyme Therapeutics (HALO) announced that it has been granted a new p ...